STipe Therapeutics

About:

STipe Therapeutics focuses on harnessing the innate immune system to battle cancer.

Website: http://www.stipetherapeutics.com/

Top Investors: Novo Holdings, Wellington Partners, BioInnovation Institute, Arix Bioscience, Life Science Venture Capital Management

Description:

STipe Therapeutics focuses on harnessing the innate immune system to battle cancer. The company has developed first-in-class drugs targeting intracellular protein-protein interactions of the STING Pathway; a major driver of innate immunity, and regulator of tumorigenesis and autoimmune disorders. The company has identified and validated compounds that sensitizes the STING pathway and by this modulates the tumor microenvironment to support a potent anti-tumoral response.

Total Funding Amount:

20M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Aarhus, Midtjylland, Denmark

Founded Date:

2018-01-01

Founders:

Claus Elsborg Olesen, Martin Roelsgaard Jakobsen

Number of Employees:

11-50

Last Funding Date:

2019-09-30

IPO Status:

Private

Industries:

© 2025 bioDAO.ai